EugeneRSchiffMD

Gastroenterology • Miami, FL

Hepatology & Liver Transplantation

Professor of Medicine, University Miami School of Medicine

Join to view full profile

Dr. Schiff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Schiff's full profile

Already have an account?

Office
Schiff Center for Liver Diseases, University of Miami
1500 NW 12 Ave, Suite 1101 East Tower
Miami, FL 33136
Phone+1 305-243-1020

Fax+1 305-243-0302
Is this information wrong?

Education & Training

University of Texas Southwestern Medical CenterFellowship, Gastroenterology, 1967 - 1969
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1966 - 1967
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1963 - 1964
University of Cincinnati Medical Center Inc.Internship, Transitional Year, 1962 - 1963
Columbia University Vagelos College of Physicians and SurgeonsClass of 1962

Certifications & Licensure

CA State Medical License 1965 - Present
FL State Medical License 1973 - 2026
OH State Medical License 1963 - 1982
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Fellow (AGAF) American Gastroenterological Association, 2007
Super Doctor SuperDoctors.com

Clinical Trials

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials Start of enrollment: 2011 Sep 01
Completed
Phase 2
HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network Start of enrollment: 2011 Nov 01
Completed
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial Start of enrollment: 2012 Feb 07
Completed
Liver Fibrosis in Sickle Cell Disease Start of enrollment: 2012 Jul 01
Completed
Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant Start of enrollment: 2014 Mar 01
Completed
Phase 3
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. Start of enrollment: 2014 Feb 01
Completed
Phase 3
Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing Start of enrollment: 2014 Feb 01
Completed
Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay Start of enrollment: 2014 Mar 01
Completed
Rapid Diagnostics for HIV and Hepatitis Start of enrollment: 2014 May 01
Withdrawn
Not Applicable
sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS Start of enrollment: 2014 Nov 14
Completed
Phase 1
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection Start of enrollment: 2014 Dec 09
Terminated
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Start of enrollment: 2014 Dec 26
Terminated
Phase 4
Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects Start of enrollment: 2015 Jan 12
Completed
Phase 1
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Start of enrollment: 2015 Sep 22
Terminated
Phase 3
Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD Start of enrollment: 2016 Jan 01
Terminated
Phase 3
Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) Start of enrollment: 2015 Dec 04
Completed
Phase 2
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis Start of enrollment: 2016 Jan 26
Completed
Phase 2
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Mar 01
Terminated
Phase 3
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Oct 24
Terminated
Phase 2
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis Start of enrollment: 2017 Feb 13
Terminated
Phase 3
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2017 Jan 30
Terminated
Phase 3
Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis Start of enrollment: 2017 Feb 14
Terminated
Phase 2
Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis Start of enrollment: 2017 Apr 06
Completed
Phase 2
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis Start of enrollment: 2017 Jun 28
Active, not recruiting
Phase 2
Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) Start of enrollment: 2017 Aug 22
Completed
Phase 2
The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology Start of enrollment: 2017 Dec 08
Terminated
Phase 2
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Start of enrollment: 2017 Aug 30
Completed
Phase 3
Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2018 Mar 21
Completed
Phase 2
Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment Start of enrollment: 2018 Jun 22
Terminated
Phase 4
Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a Start of enrollment: 2018 Dec 01
Completed
Phase 3
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2019 Jul 29
Completed
Phase 2
Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis Start of enrollment: 2019 Aug 14
Terminated
Phase 2
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection Start of enrollment: 2018 Oct 11
Recruiting
Roles: Principal Investigator, Contact
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein Start of enrollment: 2023 Mar 06
Recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

16 citations
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.
Mark S Sulkowski, Kosh Agarwal, Xiaoli Ma, Tuan T Nguyen, Eugene R Schiff, Hie-Won L Hann, Douglas T Dieterich, Ronald G Nahass, James S Park, Sing Chan, Steven-Huy B ...> ;Journal of Hepatology. 2022 Nov 1
12 citations
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.
Man-Fung Yuen, Kosh Agarwal, Xiaoli Ma, Tuan T Nguyen, Eugene R Schiff, Hie-Won L Hann, Douglas T Dieterich, Ronald G Nahass, James S Park, Sing Chan, Steven-Huy B Han...> ;Journal of Hepatology. 2022 Sep 1
4 citations
Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV
David E. Bernstein, Huy N. Trinh, Eugene R. Schiff, Coleman Smith, Andrea R. Mospan, Richard C. Zink, Michael W. Fried, Anna S. Lok> ;Digestive Diseases and Sciences. 2021 May 31
133 citations
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Samer Gawrieh, Mazen Noureddin, Nicole M. Loo, Rizwana Mohseni, Vivek Awasty, Kenneth Cusi, Kris V. Kowdley, Michelle Lai, Eugene R. Schiff, Deven Parmar, Pankaj R. Pa...> ;Hepatology. 2021 Apr 2
7 citations
Multicenter, Double‐Blind, Randomized Trial of Emricasan in Hepatitis C–Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis
Ethan M. Weinberg, Michael P. Curry, Catherine Frenette, Fredric G. Regenstein, Eugene R. Schiff, Zachary Goodman, James M. Robinson, Jean L. Chan, Joanne C. Imperial,...> ;Liver Transplantation. 2020 Dec 29
102 citations
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
Paul J. Pockros, Michael Fuchs, Bradley Freilich, Eugene R. Schiff, Anita Kohli, Eric Lawitz, Paul A. Hellstern, Janet Owens-Grillo, Courtney Van Biene, Reshma Shringa...> ;Liver International. 2019 Nov 1
68 citations
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
Mitchell L. Shiffman, Bradley Freilich, Raj Vuppalanchi, Kymberly D. Watt, Jean L. Chan, Al Spada, David T. Hagerty, Eugene R. Schiff> ;Alimentary Pharmacology & Therapeutics. 2019 Jan 1
7 citations
Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Trial of Synthetic Preimplantation Factor in Autoimmune Hepatitis
Christopher B. O'Brien, Eytan R. Barnea, Paul J. Martin, Cynthia Levy, Eden Sharabi, Kalyan Ram Bhamidimarri, Eric F. Martin, Leopold Arosemena, Eugene R. Schiff> ;Hepatology Communications. 2018 Sep 26
21 citations
Deferred treatment with sofosbuvir–velpatasvir–voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-lab...
Marc Bourlière, Stuart C. Gordon, Eugene R. Schiff, Tram T. Tran, Natarajan Ravendhran, Charles S. Landis, Robert H. Hyland, Luisa M. Stamm, Jie Zhang, Hadas Dvory-Sob...> ;The Lancet. Gastroenterology & Hepatology. 2018 Aug 1
10 citations
Obstacles to successful treatment of hepatitis C in uninsured patients from a minority population
Alexandra DeBose-Scarlett, Raymond R. Balise, Deukwoo Kwon, Susan Vadaparampil, Steven Xi Chen, Eugene R. Schiff, Gladys Patricia Ayala, Emmanuel Thomas> ;Journal of Translational Medicine. 2018 Jun 28
22 citations
Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C.
Zobair M. Younossi, Maria Stepanova, Rajender Reddy, Michael P. Manns, Marc Bourlière, Stuart C Gordon, Eugene R. Schiff, Tram Tran, Issah Younossi, Andrei Racila> ;Liver International. 2019 Jan 1
108 citations
Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection.
Emily K. Butler, Jeffrey Gersch, Anne L. McNamara, Ka Cheung Luk, Vera Holzmayer, Maria De Medina, Eugene R. Schiff, Mary C. Kuhns, Gavin Cloherty> ;Hepatology. 2018 Dec 1
28 citations
Differentiation of hepatocyte-like cells from human pluripotent stem cells using small molecules.
Faizal Z. Asumda, Konstantinos E. Hatzistergos, Derek M. Dykxhoorn, Silvia Jakubski, Jasmine Edwards, Emmanuel Thomas, Eugene R. Schiff> ;Differentiation; Research in Biological Diversity. 2018 May 1
378 citations
Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;The New England Journal of Medicine. 2017 May 31
11 citations
Barriers to Hepatitis C Screening in a Minority Population: A Comparison of Hepatitis C and Human Immunodeficiency Virus Screening Rates at a Community STD Clinic in M...
Erica B. Feldman, Raymond R. Balise, Eugene R. Schiff, Nicole Ennis Whitehead, Emmanuel Thomas> ;Journal of Community Health. 2017 Oct 1
42 citations
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
Eric Lawitz, Nancy Reau, Federico Hinestrosa, Mordechai Rabinovitz, Eugene R. Schiff, Aasim Sheikh, Ziad Younes, Robert Herring, K. Rajender Reddy, Tram Tran, Michael ...> ;Gastroenterology. 2016 Nov 1
Hepatotoxicity by herbs: a practical review of a neglected disease
Jean A. Donet, Kay Sornmayura, Matthew Gulau, Eugene R. Schiff> ;Revista De Gastroenterologia Del Peru. 2016 Oct 1
145 citations
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study
Paul Y. Kwo, Norman Gitlin, Ronald Nahass, David E. Bernstein, K.P. Etzkorn, Sergio Rojter, Eugene R. Schiff, M. Davis, Peter Ruane, Ziad Younes, R. Kalmeijer, Rekha S...> ;Hepatology. 2016 Aug 1
33 citations
Hepatitis B Virus and DNA Stimulation Trigger a Rapid Innate Immune Response through NF-κB.
Masato Yoneda, Jinhee Hyun, Silvia Jakubski, Satoru Saito, Atsushi Nakajima, Eugene R. Schiff, Emmanuel Thomas> ;Journal of Immunology. 2016 Jul 15
Early Detection of Steatohepatitis: Less Teeth NASHing and More Research?
Emmanuel Thomas, Eugene R. Schiff> ;Digestive Diseases and Sciences. 2016 Jun 1
338 citations
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence
Fred Poordad, Eugene R. Schiff, John M. Vierling, Charles S. Landis, Robert J. Fontana, Rong Yang, Fiona McPhee, Eric Hughes, Stephanie Noviello, Eugene S. Swenson> ;Hepatology. 2016 May 1
Reply.
Masato Yoneda, Emmanuel Thomas, Eugene R Schiff> ;Clinical Gastroenterology and Hepatology. 2016 Mar 1
146 citations
Effectiveness of Simeprevir Plus Sofosbuvir, with or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection
Mark S. Sulkowski, Hugo E. Vargas, Adrian M. Di Bisceglie, Alexander Kuo, K. Rajender Reddy, Joseph K. Lim, Giuseppe Morelli, Jama M. Darling, Jordan J. Feld, Robert S...> ;Gastroenterology. 2016 Feb 1
626 citations
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
, , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Gastroenterology. 2015 Sep 1
38 citations
Supersonic Shear Imaging and Transient Elastography With the XL Probe Accurately Detect Fibrosis in Overweight or Obese Patients With Chronic Liver Disease
Masato Yoneda, Emmanuel Thomas, Seth N. Sclair, Tiffannia T. Grant, Eugene R. Schiff> ;Clinical Gastroenterology and Hepatology. 2015 Aug 1
Join now to see all

Journal Articles

Differentiation of Hepatocyte-like Cells from Human Pluripotent Stem Cells Using Small Molecules
Eugene R Schiff, Emmanuel Thomas, ScienceDirect

Press Mentions

Wolfson Foundation Gifts Inspire and Challenge Medical StudentsFebruary 23rd, 2016
Hepatitis C Drugs Will 'Strain Budgets' at Current Prices: Study - US NewsMarch 16th, 2015